Equities analysts expect that Akebia Therapeutics Inc (NASDAQ:AKBA) will announce earnings of ($0.35) per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Akebia Therapeutics’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.27). Akebia Therapeutics posted earnings of ($0.60) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 41.7%. The firm is scheduled to announce its next earnings results on Wednesday, August 14th.
On average, analysts expect that Akebia Therapeutics will report full-year earnings of ($1.75) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($1.41). For the next fiscal year, analysts forecast that the business will report earnings of ($0.63) per share, with EPS estimates ranging from ($1.66) to $0.38. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Akebia Therapeutics.
Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.02). Akebia Therapeutics had a negative net margin of 82.14% and a negative return on equity of 45.06%. The business had revenue of $72.67 million for the quarter, compared to analysts’ expectations of $83.69 million.
AKBA has been the topic of a number of recent research reports. ValuEngine downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 22nd. Zacks Investment Research downgraded Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, February 11th. BidaskClub raised Akebia Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 7th. JPMorgan Chase & Co. initiated coverage on Akebia Therapeutics in a report on Thursday, May 2nd. They issued an “overweight” rating and a $12.00 target price on the stock. Finally, Citigroup initiated coverage on Akebia Therapeutics in a report on Wednesday, March 20th. They issued a “neutral” rating and a $9.00 target price on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Akebia Therapeutics presently has a consensus rating of “Hold” and an average target price of $14.03.
Shares of Akebia Therapeutics stock traded up $0.20 during trading on Tuesday, hitting $5.60. 783,742 shares of the company’s stock traded hands, compared to its average volume of 1,159,370. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.71 and a quick ratio of 1.15. Akebia Therapeutics has a 1 year low of $5.20 and a 1 year high of $11.60. The stock has a market capitalization of $650.60 million, a PE ratio of -2.30 and a beta of 1.34.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley boosted its holdings in shares of Akebia Therapeutics by 28.4% in the 1st quarter. Morgan Stanley now owns 1,327,528 shares of the biopharmaceutical company’s stock worth $10,873,000 after purchasing an additional 293,620 shares during the period. Man Group plc boosted its holdings in shares of Akebia Therapeutics by 47.9% in the 1st quarter. Man Group plc now owns 588,408 shares of the biopharmaceutical company’s stock worth $4,819,000 after purchasing an additional 190,604 shares during the period. M&T Bank Corp purchased a new position in shares of Akebia Therapeutics in the 1st quarter worth approximately $96,000. Geode Capital Management LLC boosted its holdings in shares of Akebia Therapeutics by 25.0% in the 1st quarter. Geode Capital Management LLC now owns 1,264,319 shares of the biopharmaceutical company’s stock worth $10,353,000 after purchasing an additional 252,775 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Akebia Therapeutics by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 566,940 shares of the biopharmaceutical company’s stock worth $4,644,000 after purchasing an additional 6,680 shares during the period. 68.58% of the stock is currently owned by hedge funds and other institutional investors.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Featured Article: Why do commodities matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.